Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iNK in advanced solid tumors
NCT06245018Phase 1Not yet recruiting
- Sponsor
- Nuwacell Biotechnologies
- Start
- Feb 2024
- Primary completion
- Mar 2027
- Modality
- Patient-derived iPSCs, Lymphokine-Activated Killer Cells, Allogeneic iPSCs
01
Overview
Phase 1, open-label, single-arm trial of iPSC-derived natural killer cells in solid tumor, sponsored by Nuwacell Biotechnologies. Primary endpoints: Adverse Event at 1 year and Dose-Limiting Toxicity at 4 weeks. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
iPSC-derived natural killer cells
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06245018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06245018.